NEW YORK (GenomeWeb News) – Genalyte today announced it has inked distribution deals for its Maverick Detection System covering parts of Europe.

The system, which analyzes multiple antibodies and other proteins, also received the CE Mark for research use in Europe.

San Diego-based Genalyte has reached distribution deals with Mokascience in France; Bucher Biotec in Switzerland; and KRD Molecular Technologies in the Czech Republic, Slovakia, and Hungary. The deals are the firm's first in Europe, it noted.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.